Lisa Prior1,2, Hannah Featherstone3,4, David O'Reilly3,4, Killian Nugent3,4, Marvin Lim3,4, John McCaffrey3,4, Michaela J Higgins3,4, Catherine M Kelly3,4. 1. Department of Medical Oncology, Mater Misericordiae University Hospital, Eccles St, Dublin, D07 R2WY, Ireland. lisaprior88@gmail.com. 2. UCD (University College Dublin) School of Medicine, Belfield, Dublin 4, Ireland. lisaprior88@gmail.com. 3. Department of Medical Oncology, Mater Misericordiae University Hospital, Eccles St, Dublin, D07 R2WY, Ireland. 4. UCD (University College Dublin) School of Medicine, Belfield, Dublin 4, Ireland.
Abstract
BACKGROUND: Due to advances in care, most women diagnosed with breast cancer do not die from the disease itself. Instead, cardiovascular disease (CVD) remains the most frequent cause of death. Many breast cancer patients are older and have established CVD risk factors. They are at further risk due to exposure to anthracyclines, HER2 targeted agents, endocrine therapy and radiotherapy. In this study, we compared the 10-year predicted risk of breast cancer mortality versus that of cardiovascular (CV) morbidity/mortality in breast cancer patients receiving adjuvant chemotherapy using online predictive risk calculators. Furthermore, we evaluated the predicted outcome of CV risk factor optimisation on their overall CV risk. METHODS: This was a cross sectional study. All patients with resected Stage I-III breast cancer who received adjuvant chemotherapy at our centre from September 2015 to November 2016 were identified. Data recorded included demographics, tumor characteristics, treatments and CV risk factors. To calculate predicted 10-year risk of CVD and impact of lifestyle changes, we used the JBS3 (Joint British Society) online risk calculator. To calculate the predicted 10-year risk of breast cancer mortality, we used the PREDICT calculator. Biostatistical methods included Wilcoxon signed rank test for predicted CVD risk pre and post cardiovascular risk optimization. RESULTS: We identified 102 patients. Of this cohort, 76 patients were ≥ 50 years & 26 were < 50 years of age. The group had significant baseline cardiovascular risk factors: increased BMI (68 %, n = 70), ex-smoking (34 %, n = 35), current smoking (13 %, n = 13), hypertension (47 %, n = 47) and dyslipidemia (57 %). Of the total group, 48 % had a high (> 20 %) and 37 % had a moderate (10-20 %) 10-year predicted breast cancer mortality risk. Regarding 10-year predicted risk of CVD, 11 % and 22 % fell into the high (> 20 %) and moderate (10-20 %) risk categories, respectively. Assuming CV risk factor optimisation, there was a predicted improvement in median 10-year CV risk from 26.5 to 9.9 % (p = .005) in the high CVD risk group and from 14.0 to 6.6 % (p < .001) in the moderate CVD risk group. CONCLUSIONS: Benefits predicted with a CVD risk intervention model indicates that this should be incorporated into routine breast oncology care.
BACKGROUND: Due to advances in care, most women diagnosed with breast cancer do not die from the disease itself. Instead, cardiovascular disease (CVD) remains the most frequent cause of death. Many breast cancerpatients are older and have established CVD risk factors. They are at further risk due to exposure to anthracyclines, HER2 targeted agents, endocrine therapy and radiotherapy. In this study, we compared the 10-year predicted risk of breast cancer mortality versus that of cardiovascular (CV) morbidity/mortality in breast cancerpatients receiving adjuvant chemotherapy using online predictive risk calculators. Furthermore, we evaluated the predicted outcome of CV risk factor optimisation on their overall CV risk. METHODS: This was a cross sectional study. All patients with resected Stage I-III breast cancer who received adjuvant chemotherapy at our centre from September 2015 to November 2016 were identified. Data recorded included demographics, tumor characteristics, treatments and CV risk factors. To calculate predicted 10-year risk of CVD and impact of lifestyle changes, we used the JBS3 (Joint British Society) online risk calculator. To calculate the predicted 10-year risk of breast cancer mortality, we used the PREDICT calculator. Biostatistical methods included Wilcoxon signed rank test for predicted CVD risk pre and post cardiovascular risk optimization. RESULTS: We identified 102 patients. Of this cohort, 76 patients were ≥ 50 years & 26 were < 50 years of age. The group had significant baseline cardiovascular risk factors: increased BMI (68 %, n = 70), ex-smoking (34 %, n = 35), current smoking (13 %, n = 13), hypertension (47 %, n = 47) and dyslipidemia (57 %). Of the total group, 48 % had a high (> 20 %) and 37 % had a moderate (10-20 %) 10-year predicted breast cancer mortality risk. Regarding 10-year predicted risk of CVD, 11 % and 22 % fell into the high (> 20 %) and moderate (10-20 %) risk categories, respectively. Assuming CV risk factor optimisation, there was a predicted improvement in median 10-year CV risk from 26.5 to 9.9 % (p = .005) in the high CVD risk group and from 14.0 to 6.6 % (p < .001) in the moderate CVD risk group. CONCLUSIONS: Benefits predicted with a CVD risk intervention model indicates that this should be incorporated into routine breast oncology care.
Entities:
Keywords:
Breast cancer; Cardiovascular disease; Cardiovascular risk factor; Risk prevention
Authors: Guy De Backer; Ettore Ambrosioni; Knut Borch-Johnsen; Carlos Brotons; Renata Cifkova; Jean Dallongeville; Shah Ebrahim; Ole Faergeman; Ian Graham; Giuseppe Mancia; Volkert Manger Cats; Kristina Orth-Gomér; Joep Perk; Kalevi Pyörälä; José L Rodicio; Susana Sans; Vedat Sansoy; Udo Sechtem; Sigmund Silber; Troels Thomsen; David Wood Journal: Eur J Cardiovasc Prev Rehabil Date: 2003-08
Authors: Laxmi S Mehta; Karol E Watson; Ana Barac; Theresa M Beckie; Vera Bittner; Salvador Cruz-Flores; Susan Dent; Lavanya Kondapalli; Bonnie Ky; Tochukwu Okwuosa; Ileana L Piña; Annabelle Santos Volgman Journal: Circulation Date: 2018-02-01 Impact factor: 29.690
Authors: Gilles R Dagenais; Darryl P Leong; Sumathy Rangarajan; Fernando Lanas; Patricio Lopez-Jaramillo; Rajeev Gupta; Rafael Diaz; Alvaro Avezum; Gustavo B F Oliveira; Andreas Wielgosz; Shameena R Parambath; Prem Mony; Khalid F Alhabib; Ahmet Temizhan; Noorhassim Ismail; Jephat Chifamba; Karen Yeates; Rasha Khatib; Omar Rahman; Katarzyna Zatonska; Khawar Kazmi; Li Wei; Jun Zhu; Annika Rosengren; K Vijayakumar; Manmeet Kaur; Viswanathan Mohan; AfzalHussein Yusufali; Roya Kelishadi; Koon K Teo; Philip Joseph; Salim Yusuf Journal: Lancet Date: 2019-09-03 Impact factor: 79.321
Authors: Jackson T Wright; Jeff D Williamson; Paul K Whelton; Joni K Snyder; Kaycee M Sink; Michael V Rocco; David M Reboussin; Mahboob Rahman; Suzanne Oparil; Cora E Lewis; Paul L Kimmel; Karen C Johnson; David C Goff; Lawrence J Fine; Jeffrey A Cutler; William C Cushman; Alfred K Cheung; Walter T Ambrosius Journal: N Engl J Med Date: 2015-11-09 Impact factor: 91.245
Authors: Sofie A M Gernaat; Jolanda M A Boer; Desiree H J van den Bongard; Angela H E M Maas; Carmen C van der Pol; Rhodé M Bijlsma; Diederick E Grobbee; Helena M Verkooijen; Petra H Peeters Journal: Breast Cancer Res Treat Date: 2018-02-28 Impact factor: 4.872
Authors: Dongshan Zhu; Hsin-Fang Chung; Annette J Dobson; Nirmala Pandeya; Graham G Giles; Fiona Bruinsma; Eric J Brunner; Diana Kuh; Rebecca Hardy; Nancy E Avis; Ellen B Gold; Carol A Derby; Karen A Matthews; Janet E Cade; Darren C Greenwood; Panayotes Demakakos; Daniel E Brown; Lynnette L Sievert; Debra Anderson; Kunihiko Hayashi; Jung Su Lee; Hideki Mizunuma; Therese Tillin; Mette Kildevæld Simonsen; Hans-Olov Adami; Elisabete Weiderpass; Gita D Mishra Journal: Lancet Public Health Date: 2019-10-03